[Form 4] Reneo Pharmaceuticals, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

OnKure Therapeutics (OKUR) President, CEO, and Director Nicholas A. Saccomano reported an insider transaction on Form 4 filed June 25, 2025, detailing activity that occurred on June 23, 2025.

Key transaction details:

• Disposed of 88 shares of Class A Common Stock at a weighted average price of $2.3842 per share
• Transaction was an automatic sale (S) to cover tax withholding obligations related to vesting RSUs
• Following the transaction, Saccomano holds 3,594 shares directly

The shares were sold in multiple trades ranging from $2.33 to $2.47 per share. The transaction was executed under the company's 2023 RSU Equity Incentive Plan. The filing was signed by Rogan Nunn via power of attorney.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saccomano Nicholas A

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/23/2025		S(1)		88	D	$2.3842(2)	3,594(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

2. This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

	/s/ Rogan Nunn, by power of attorney	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did RPHM's President and CEO Nicholas Saccomano sell on June 23, 2025?

Nicholas Saccomano sold 88 shares of Class A Common Stock on June 23, 2025 at a weighted average price of $2.3842 per share. These shares were automatically sold to cover tax withholding obligations related to vesting RSUs.

What was the price range for RPHM insider trading transaction on June 23, 2025?

The shares were sold in multiple trades at prices ranging from $2.33 to $2.47 per share, with a weighted average sale price of $2.3842.

How many RPHM shares does Nicholas Saccomano own after the June 23, 2025 transaction?

Following the reported transaction, Nicholas Saccomano directly owns 3,594 shares of RPHM, some of which are Restricted Stock Units (RSUs) that represent contingent rights to receive Class A Common Stock subject to vesting conditions.

Why did RPHM's CEO Nicholas Saccomano sell shares on June 23, 2025?

The shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This was not a discretionary sale by the CEO.